Doravirine/lamivudine/tenofovir disoproxil

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Doravirine/lamivudine/tenofovir disoproxil
Combination of
DoravirineNon-nucleoside reverse transcriptase inhibitor
LamivudineNucleoside reverse transcriptase inhibitor
Tenofovir disoproxilNucleotide reverse transcriptase inhibitor
Clinical data
Trade namesDelstrigo
ATC code

Doravirine/lamivudine/tenofovir disoproxil (brand name Delstrigo) is a fixed-dose combination drug for the treatment of HIV/AIDS.[1] It contains doravirine, lamivudine, and tenofovir disoproxil.[2] In the United States, it was approved by the Food and Drug Administration in August 2018 for the treatment of HIV-1 infection.[2]


  1. ^ "Doravirine/lamivudine/tenofovir disoproxil fumarate - Merck & Co". Adis Insight.
  2. ^ a b "FDA Approves Merck's DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in Appropriate Patients" (Press release). Merck & Co. August 30, 2018.